Product Description
Mechanisms of Action: DBH Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Acorda
Company Location: ARDSLEY NY 10502
Company CEO: Ron Cohen
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Stress Disorders, Post-Traumatic|Cocaine-Related Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NIDA/VA CS#1031 | P2 |
Completed |
Cocaine-Related Disorders |
2014-08-01 |
|
| Nepicastat | P2 |
Completed |
Stress Disorders, Post-Traumatic |
2012-07-05 |
|
| H22601 | P2 |
Withdrawn |
Stress Disorders, Post-Traumatic |
2009-09-01 |
|
| SYN117-CL01 | P2 |
Completed |
Cocaine-Related Disorders |
2009-05-01 |
29% |